Different SARS-CoV-2 variants inhibited by RRM designed peptide
PLOS One · 22.07.2025 · 20 (7) · e0327582
DOI: 10.1371/journal.pone.0327582 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 22.07.2025. Verfasst von Uros Krapez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Poultry, Birds, Small Mammals, and Reptiles, Veterinary Faculty, University of Ljubljana, Ljubljana, Slovenia. Hauptthemen laut MEDLINE: SARS-CoV-2, Peptides, Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The SARS-CoV-2 virus has mutated over time, resulting in variations of circulating viral variants, which may impact the virus’s properties, such as transmission or the severity of symptoms. Thus, there is a need for comprehensive approach less dependent of viral variants. For that purpose, we have employed the innovative and unique Resonant Recognition Model (RRM) to identify the common characteristics of all variants of SARS-CoV-2 virus and based on these characteristics, we have explored the possibility to develop approach against SARS-CoV-2 infection, less dependent on viral variants. This paper is a continuation of our previous research, where we have used the RRM model to design de novo peptide CovA, capable to prevent SARS-CoV-2 interaction with ACE2 receptor on host cells. Using Inhibitor Screening Assay Kits and viral replication in SARS-CoV-2/Vero E6 cells model, it has been previously shown that CovA can prevent viral interaction with receptor and viral replication in host cells. This test has been done on Wuhan variant only. Here, we have tested this RRM designed peptide CovA for efficiency with some other different SARS-CoV-2 variants. It has been shown here, that CovA act on all tested viral variants, but with different efficiency. Apart from representing the basis of new COVID-19 drugs discovery, this research once again presents the ability of RRM model to design de novo bioactive peptides with desired biological function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute for Poultry, Birds, Small Mammals, and Reptiles, Veterinary Faculty, University of Ljubljana, Ljubljana, Slovenia.
- Institute of Microbiology and Parasitology, Veterinary Faculty, University of Ljubljana, Ljubljana, Slovenia.
- AMALNA Consulting, Black Rock, Melbourne, VIC, Australia.
- QuantBioRes - QBR A/S, Copenhagen, Denmark.
- National Laboratory for Health, Environment and Food, Maribor, Slovenia.
ORCID-Profile: Petra Šenica, Irena Cosic
Zitieren
APA
Krapez, U., Kuhar, U., Šenica, P., Slavec, B., Cosic, D., Loncarevic, I., Janezic, S., & Cosic, I. (2025). Different SARS-CoV-2 variants inhibited by RRM designed peptide. PLOS One, 20(7), e0327582. https://doi.org/10.1371/journal.pone.0327582
Vancouver
Krapez U, Kuhar U, Šenica P, Slavec B, Cosic D, Loncarevic I, et al. Different SARS-CoV-2 variants inhibited by RRM designed peptide. PLOS One. 2025;20(7):e0327582. doi:10.1371/journal.pone.0327582
BibTeX
@article{Krapez2025,
author = {Krapez, Uros and Kuhar, Urska and Šenica, Petra and Slavec, Brigita and Cosic, Drasko and Loncarevic, Ivan and Janezic, Sandra and Cosic, Irena},
title = {Different SARS-CoV-2 variants inhibited by RRM designed peptide},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {7},
pages = {e0327582},
doi = {10.1371/journal.pone.0327582}
}
EUVIMED